355 related articles for article (PubMed ID: 31008868)
21. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.
Dong J; Buas MF; Gharahkhani P; Kendall BJ; Onstad L; Zhao S; Anderson LA; Wu AH; Ye W; Bird NC; Bernstein L; Chow WH; Gammon MD; Liu G; Caldas C; Pharoah PD; Risch HA; Iyer PG; Reid BJ; Hardie LJ; Lagergren J; Shaheen NJ; Corley DA; Fitzgerald RC; ; Whiteman DC; Vaughan TL; Thrift AP
Gastroenterology; 2018 Apr; 154(5):1273-1281.e3. PubMed ID: 29247777
[TBL] [Abstract][Full Text] [Related]
22. Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study.
Murphy SJ; Anderson LA; Johnston BT; Fitzpatrick DA; Watson PR; Monaghan P; Murray LJ
World J Gastroenterol; 2005 Dec; 11(46):7290-5. PubMed ID: 16437630
[TBL] [Abstract][Full Text] [Related]
23. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
Menges M; Müller M; Zeitz M
Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
[TBL] [Abstract][Full Text] [Related]
24. The Present Status and Future of Barrett's Esophageal Adenocarcinoma in Japan.
Nishi T; Makuuchi H; Ozawa S; Shimada H; Chino O
Digestion; 2019; 99(2):185-190. PubMed ID: 30481763
[TBL] [Abstract][Full Text] [Related]
25. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present.
Singh P; Taylor RH; Colin-Jones DG
Am J Gastroenterol; 1994 Mar; 89(3):349-56. PubMed ID: 8122643
[TBL] [Abstract][Full Text] [Related]
26. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
27. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.
Wennerström EC; Risques RA; Prunkard D; Giffen C; Corley DA; Murray LJ; Whiteman DC; Wu AH; Bernstein L; Ye W; Chow WH; Vaughan TL; Liao LM
Cancer Med; 2016 Sep; 5(9):2657-65. PubMed ID: 27384379
[TBL] [Abstract][Full Text] [Related]
28. Barrett's esophagus and medications that relax the lower esophageal sphincter.
Corley DA; Levin TR; Habel LA; Buffler PA
Am J Gastroenterol; 2006 May; 101(5):937-44. PubMed ID: 16573773
[TBL] [Abstract][Full Text] [Related]
29. Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
Ekiz F; Ormeci N; Coban S; Karabulut HG; Aktas B; Tukun A; Tuncali T; Yüksel O; Alkış N
Dis Esophagus; 2012 Jul; 25(5):437-41. PubMed ID: 21951971
[TBL] [Abstract][Full Text] [Related]
30. Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ; Wong RK
Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
[TBL] [Abstract][Full Text] [Related]
31. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Bytzer P; Christensen PB; Damkier P; Vinding K; Seersholm N
Am J Gastroenterol; 1999 Jan; 94(1):86-91. PubMed ID: 9934736
[TBL] [Abstract][Full Text] [Related]
32. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
33. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
34. Dietary magnesium, calcium:magnesium ratio and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
Dai Q; Cantwell MM; Murray LJ; Zheng W; Anderson LA; Coleman HG;
Br J Nutr; 2016 Jan; 115(2):342-50. PubMed ID: 26563986
[TBL] [Abstract][Full Text] [Related]
35. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?
Gough MD; Ackroyd R; Majeed AW; Bird NC
Am J Gastroenterol; 2005 May; 100(5):1012-8. PubMed ID: 15842572
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
37. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
38. Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China.
Liu S; Dai JY; Yao L; Li X; Reid B; Self S; Ma J; Chang Y; Feng S; Tapsoba Jde D; Sun X; Sun X
PLoS One; 2014; 9(10):e110348. PubMed ID: 25333822
[TBL] [Abstract][Full Text] [Related]
39. The value of medical imaging in uncomplicated and complicated Barrett's esophagus.
De Backer AI; De Schepper AM; Pelckmans P
Acta Gastroenterol Belg; 2000; 63(1):22-8. PubMed ID: 10907315
[TBL] [Abstract][Full Text] [Related]
40. Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer.
D'Onofrio V; Bovero E; Iaquinto G
Dis Esophagus; 1997 Jan; 10(1):16-22; discussion 22-3. PubMed ID: 9079268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
